IOPIDINE 5mg/ml is indicated for short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery. The IOP lowering efficacy of IOPIDINE diminishes over time in most patients. Although some patients have received successful treatment with IOPIDINE for longer periods, the benefit for most patients is less than one month. The addition of IOPIDINE to patients already using two aqueous suppressing drugs (i.e. beta-blockers plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because IOPIDINE is an aqueous suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP.
IOPIDINE 1% is indicated to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. (Clinical trials have been conducted in trabeculoplasty, iridotomy and capsulotomy).
NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
Merck has announced y that it signed an agreement for Santen Pharmaceutical Co., Ltd. to purchase Merck�s ophthalmology products, Cosopt...